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Plasma phospholipid transfer protein (PLTP) is
thought to be involved in the remodeling of high density
lipoproteins (HDL), which are atheroprotective. It is
also involved in the metabolism of very low density li-
poproteins (VLDL). Hence, PLTP is thought to be an
important factor in lipoprotein metabolism and the de-
velopment of atherosclerosis. We have overexpressed
PLTP in mice heterozygous for the low density lipopro-
tein (LDL) receptor, a model for atherosclerosis. We
show that increased PLTP activity results in a dose-de-
pendent decrease in HDL, and a moderate stimulation of
VLDL secretion (<1.5-fold). The mice were given a high
fat, high cholesterol diet, which resulted in hypercho-
lesterolemia in all animals. HDL concentrations were
dramatically reduced in PLTP-overexpressing animals
when compared with LDL receptor controls, whereas
VLDL  LDL cholesterol levels were identical. Suscep-
tibility to atherosclerosis was increased in a PLTP dose-
responsive manner. We conclude that PLTP increases
susceptibility to atherosclerosis by lowering HDL con-
centrations, and therefore we suggest that an increase
in PLTP is a novel, long term risk factor for atheroscle-
rosis in humans.
High density lipoproteins (HDL)1 are believed to be protec-
tive against the development of atherosclerosis because they
mediate reverse cholesterol transport, i.e. the transfer of cho-
lesterol from peripheral tissues to the liver (1, 2). However, our
understanding of the molecular details and key regulatory
proteins involved is incomplete (3–5). One effector of this proc-
ess is the ATP-binding cassette ABCA1, which is functionally
deficient in Tangier disease (reviewed in Ref. 6). The high
incidence of coronary artery disease in Tangier patients sug-
gests an essential, protective role of HDL-mediated reverse
cholesterol transport in the development of atherosclerosis (7).
However, recent results suggest that the contribution of
ABCA1 to overall reverse cholesterol transport and its role in
atherogenesis are primarily related to its function in macro-
phages (8–10). Therefore, other potential key proteins in re-
verse cholesterol transport are of interest, including PLTP
(11–13).
Previously, we generated transgenic mice overexpressing hu-
man PLTP and showed that plasma from these animals is more
effective in preventing accumulation of cholesterol by cultured
macrophages (14). We and others therefore suggested an anti-
atherogenic effect for PLTP (14–16). On the other hand, over-
expression of PLTP results in a decrease of plasma HDL levels
(14, 17, 18), which could be an atherogenic effect. Thus, it is
unclear whether the net effect of high PLTP activity levels
would be atherogenic or anti-atherogenic. The complete ab-
sence of PLTP activity in PLTP knockout mice inhibits HDL
maturation, which results in reduced levels of plasma HDL
caused by accelerated decay (19, 20). Still, PLTP knockout mice
showed decreased atherosclerosis (21). This could be partly
explained by the discovery of a novel, intracellular function of
PLTP in hepatocytes; it was found that PLTP deficiency caused
a decrease in apolipoprotein (apo) B-containing lipoproteins in
most but not all mouse models used (21). From these results, it
was concluded that PLTP is involved in VLDL secretion (21).
To clearly establish the relationship between variability in
PLTP activity and the development of atherosclerosis, we cre-
ated a series of transgenic mice with various levels of PLTP
activities. The susceptibility to diet-induced atherosclerosis
was studied in these mice and related to changes in plasma
lipoproteins.
EXPERIMENTAL PROCEDURES
Transgene Design and Development—The isolation of a cosmid clone
with the complete human PLTP gene including its natural flanking
sequences was described previously (14). A DNA construct for the
generation of mice with liver-specific expression of PLTP was generated
from this cosmid using mouse albumin promoter and enhancer se-
quences (equivalent to construct NB (22), kindly donated by Dr. R. D.
Palmiter, Seattle, WA) and -fetoprotein enhancer sequences (kindly
donated by Dr. S. M. Tilghman, Princeton, NJ). The PLTP sequences
upstream from exon 1 were removed, and a 2.3-kb NotI-BamHI frag-
ment, including the albumin promoter and enhancer sequences, was
cloned into the BamHI site in exon 1 of the PLTP gene. A 6.5-kb
genomic fragment containing the three -fetoprotein enhancer ele-
ments (shown to interact with the albumin promoter to result in high
liver expression) (23) was cloned into the EcoRV site 1.5 kb downstream
of the last exon of the PLTP gene (exon 16, containing the STOP codon).
The cloning strategy necessitated the replacement of the genomic se-
quence between the BamHI sites in exons 5 and 8 by the equivalent
cDNA sequence (264 bp).
Mice—Transgenic mice were obtained by microinjection of fertilized
oocytes as described before (14). The P1 transgenic line was originally
described in Ref. 14. All of the mice used in this study were 96%
C57BL/6J (N5) male mice. LDLR/ mice in C57BL/6J were purchased
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from Jackson Laboratory. Controls were littermates. The mice were 12
weeks old at the beginning of the diet studies.
The mice were fed either a chow diet or an atherogenic high fat, high
cholesterol diet containing 40% (w/w) sucrose, 15% (w/w) cocoa butter,
1% (w/w) cholesterol, and 0.5% (w/w) cholate (diet N; Hope Farms,
Woerden, The Netherlands) for 12 weeks, preceeded by 2 weeks of diet
containing 50% (w/w) sucrose (diet J; Hope Farms). Plasma samples
were collected by orbital bleedings after fasting the animals overnight.
All of the procedures in this study were in accordance with national and
institutional guidelines.
Gene Expression Analysis by Reverse Transcription-PCR—For RNA
isolation studies, the mice were killed by cervical dislocation, and the
organs were quickly removed and frozen in liquid nitrogen. The tissue
was either stored at 80 °C or processed immediately. Total RNA was
isolated using the Ultraspec RNA isolation reagent from Biotecx Lab-
oratories Inc. (Houston, TX) and used as a template for reverse tran-
scription primed by oligo(dT). RNA expression was analyzed by reverse
transcription-PCR (14). PCR products were run on polyacrylamide gels
and visualized by autoradiography on Kodak BioMax MR-1 films or by
using a PhosphorImager (Amersham Biosciences). Details on the
primer sets used, and PCR conditions are available upon request via
E-mail.
FIG. 1. Generation of PLTP transgenic mice. a, lines P1 and P4
have been generated with fragment 1, comprising the unmodified hu-
man PLTP gene, 15 kb 5 and 3.5 kb 3 of the natural flanking regions.
Lines A2 and A3 have been generated with fragment 2, in which the
mouse albumin promoter and enhancer is located 5 to the PLTP gene,
and -fetoprotein enhancer sequences have been added at the 3 end of
the construct. b, mRNA analyses of the human PLTP transgene. Lane
C, wild type littermates. c, mRNA expression of various mouse genes in
liver. Lane C, wild type littermates.
FIG. 2. Plasma levels of PLTP activity, cholesterol and apoAI
in PLTP transgenic mice. PLTP activity (a) and cholesterol concen-
tration (b) were measured in plasma samples from 7–12 PLTP trans-
genic mice or wild type littermates (lane C). *, p  0.005; **, p  0.001
versus control. c, upper panel, apoAI detected by staining of SDS-
polyacrylamide gel with Coomassie Brilliant Blue. Plasma samples
from six mice were pooled, and HDL was isolated by gradient ultracen-
trifugation. The samples corresponding to 12 l of plasma were applied
to the gel. Lower panel, three gels were scanned and quantified using
ImageQuant software (Molecular Dynamics). *, p  0.001 versus wild
type littermates. All of the values are expressed as the means  S.D.
FIG. 3. Plasma levels of PLTP activity and cholesterol in trans-
genic PLTP, LDLR/ mice. PLTP activity (a) and cholesterol concentra-
tion (b) were measured in plasma samples from 15–19 animals. All of the
values are expressed as the meansS.D. *, p 0.001 versus LDLR/mice.
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Lipoproteins and PLTP Analysis—Lipoprotein fractions were ob-
tained by ultracentrifugation of plasma samples in a Beckman 42.2 Ti
rotor (42000 rpm, 3 h, 12 °C) at d  1.063 g/ml. The tubes were sliced,
and two fractions were collected: VLDL  LDL, d  1.063 g/ml; and
HDL, d  1.063 g/ml. Alternatively, the lipoprotein fractions were
isolated by gradient ultracentrifugation in a Beckman SW60 Ti rotor
(24). The total cholesterol was measured with commercial kits (Roche
Molecular Biochemicals). PLTP activity was measured as described
before (14) and expressed as a percentage of human reference plasma
(100% is equivalent to 14 mol/ml/h).
VLDL Triglyceride Secretion Experiments—The in vivo production of
triglycerides by the liver, secreted as VLDL, was measured in mice that
were fasted overnight. 500 mg/kg body weight of Triton WR1339 (Tylox-
apol; Sigma) was injected intravenously. At 1, 30, and 60 min after
injection, 40 l of blood was collected via orbital puncture. At 90 min
after the injection, the mice were sacrificed, and an additional large
blood sample was collected. From these samples, VLDL was isolated by
gradient ultracentrifugation. Triglyceride levels in each of the blood
samples as well as triglycerides, free cholesterol, cholesterol esters, and
phospholipids in VLDL were determined via commercially available
kits (25). The accumulation of triglycerides in plasma was linear in the
time period studied. From the slope, the rate of secretion was calculated
and related to the body weight of the animals (n  5–9 animals/group).
A small number of animals was injected intravenously with 100 Ci of
[35S]methionine (ICN, Zoetermeer, The Netherlands).
Quantification of Atherosclerosis—After 12 weeks of the high fat,
high cholesterol diet, the animals were anesthesized with isofluran, the
thorax was opened, and the animals were subjected to perfusion fixa-
tion through the left ventricle of the heart using phosphate-buffered 4%
formalin. The heart and aortic arch were dissected and processed for
cryosectioning. 10-m cryosections of the valves in the aortic root were
stained with Oil Red O and Mayer’s hematoxilin. The sections were
photographed with a Sony digital camera. The atherosclerotic area was
measured in five sections at 80-m intervals using the NIH Image
based Scion Image image processing and analyzing software (available
from www.scioncorp.com) according to Paigen et al. (26).
Statistics—All of values are expressed as the means  S.D. Statis-
tical analyses are from one-way analysis of variance with Bonferroni
multiple comparison tests performed with Intercooled Stata 6.0 soft-
ware (Stata Corp., College Station, TX).
RESULTS
Overexpression of PLTP Decreases Plasma HDL—To inves-
tigate variation in PLTP expression levels as a risk for the
development of atherosclerosis, we generated several lines of
transgenic mice overexpressing various levels of human PLTP.
These mice were made with two genomic constructs in which
FIG. 4. Secretion of VLDL triglycer-
ides in transgenic PLTP, LDLR/
mice. a, blood was collected at 1, 30, 60,
and 90 min after intravenous injection of
Triton WR1339, and triglycerides were
measured. E, LDLR/ mice; , P1/
LDLR/ mice, ƒ A2/LDLR/ mice. b,
secretion rate of triglycerides/kg of body
weight. *, p  0.001 versus LDLR/
mice. c, autoradiograms of VLDL, isolated
from t  90 min blood samples and ap-
plied to SDS-PAGE gels. Two representa-
tive samples from individual mice are
shown. d, lipid composition of VLDL (w/w
of total lipids).
TABLE I
PLTP activity and plasma cholesterol in mice fed an atherogenic diet
Total cholesterol (TC) is expressed in mM; PLTP activity is expressed as percentages of human reference plasma.
n
4 weeks 12 weeks
PLTP TC PLTP TC VLDL/LDL TC HDL TC
LDLR/ 19 358  94 13.4  5.4 329  130 11.0  2.2 8.2  1.8 1.32  0.51
P1/LDLR/ 17 762  74a 10.8  2.9a 662  99 9.6  3.1 7.9  2.9 0.55  0.23b
P4/LDLR/ 19 1081  256b 12.2  3.3 1030  179c 10.7  3.1 7.8  2.3 0.21  0.08b
A2/LDLR/ 13 4023  1328b 12.3  2.7 4583  1705b 9.6  4.8 6.7  2.9 0.16  0.07b
A3/LDLR/ 17 1088  223b 11.6  4.5 956  245c 10.1  5.2 7.8  3.4 0.24  0.14b
a Significantly different from LDLR/, p  0.05.
b Significantly different from LDLR/, p  0.01.
c Significantly different from LDLR/, p  0.001.
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PLTP expression is either under the control of its native pro-
moter, resulting in the normal, multi-organ expression pattern
of PLTP (14, 16, 27, 28), or under the control of the albumin
promoter together with the albumin enhancer and -fetopro-
tein enhancers, resulting in expression in hepatocytes. The
mouse lines with these constructs were arbitrarily called P1 or
P4 (multi-organ expression) and A2 or A3 (expression in hepa-
tocytes), respectively (Fig. 1a). The expression of human PLTP
was investigated by reverse transcription-PCR, using primers
specific for human PLTP. As shown in Fig. 1b, there is no signal
from endogenous, murine PLTP in control, nontransgenic ani-
mals. Human PLTP mRNA can be detected in liver, adrenal
glands, and lung, and, to a lesser extent, in kidney in P1 and P4
mice. A2 and A3 mice expressed the transgene predominantly
in liver. The level of hepatic mRNA is much higher in the A2
and A3 lines when compared with the P1 and P4 lines. Human
PLTP mRNA was also detected in lungs in the A2 line mice;
however, the expression in liver is much more prominent. The
expression in liver of murine PLTP, studied with primers spe-
cific for murine PLTP, and other genes encoding proteins in-
volved in HDL metabolism were not altered by overexpression
of human PLTP (Fig. 1c).
Plasma PLTP activity levels in the different lines of trans-
genic mice ranged from 2-fold (P1 mice) to 9-fold (A2 mice)
higher than the activity in wild type littermates (Fig. 2a).
Cholesterol concentration decreases with increasing PLTP ac-
tivity in plasma from these transgenic mouse lines to less than
10% of the normal levels in the A2 mice (Fig. 2b). Because
plasma cholesterol in mice is mainly in HDL, the decrease in
cholesterol should be reflected by a decrease of this class of
lipoproteins. Fig. 2c confirms that the most prominent protein
in HDL, apoAI, decreases with increasing PLTP activity to
levels below detection in the A2 mice (Fig. 2c).
In contrast to humans, mice lack substantial levels of plasma
LDL and hardly develop atherosclerosis. Therefore, we cross-
bred human PLTP transgenic mice into an LDLR/ back-
ground, which has been shown to be a good model for moderate
atherosclerosis development (29). This background results in
an increase in PLTP activity: 360  80% (n  19) in LDLR/
mice versus 266  47% (n  12) in wild type mice (p  0.02;
compare Fig. 3a with Fig. 2a). Also in mice with LDLR/
background, there is an inverse correlation between PLTP ac-
tivity and cholesterol levels in plasma (Fig. 3). As expected, the
plasma cholesterol levels were higher in LDLR/ mice: 3.5 
0.6 mM (n  19) versus 2.2  0.3 mM (n  12) in C57BL/6J wild
type mice (p  0.0001). However, in the transgenic lines with
substantially elevated PLTP levels (P4/LDLR/, A3/LDLR/,
and A2/LDLR/ mice), plasma cholesterol was decreased to
levels below those found in the wild type control animals
(LDLR/; compare Fig. 3b with Fig. 2b).
Overexpression of PLTP Results in a Moderate Increase in
VLDL Secretion—Because PLTP deficiency impairs VLDL se-
cretion by the liver (21), we tested whether overexpression of
PLTP would result in increased VLDL triglyceride secretion.
We made a comparison between control LDLR/ mice and
P1/LDLR/, which is the transgenic line with the lowest ex-
pression of PLTP, and A2/LDLR/ mice, which have the high-
est expression of PLTP. In addition, hepatic expression of PLTP
is greatly increased in A2/LDLR/ mice (Fig. 1b), and thus a
hepatocyte-specific effect should be highly augmented in these
animals. Hepatic triglyceride secretion appeared to be in-
creased by PLTP overexpression but only to a moderate extent
(Fig. 4a). The rate of triglyceride secretion was only 1.3- and
1.5-fold higher than in control animals in P1/LDLR/ mice
and A2/LDLR/ mice, respectively (Fig. 4b). PLTP overex-
pression did not induce any gross changes in the ratio of
apoB100/apoB48 (Fig. 4c). The lipid composition of secreted
VLDL was similar in the three groups (Fig. 4d).
Overexpression of PLTP Increases the Susceptibility to Ath-
erosclerosis—Subsequently, mice from each of the five groups
tested in Fig. 3 were fed a high fat, high cholesterol diet for 12
weeks. The plasma levels of total cholesterol were highly in-
creased after 4 weeks, to 13.4  5.4 mM in LDLR/ control
mice (versus 3.5  0.6 mM before the diet). The overexpression
of human PLTP did not seem to affect this, because the high
plasma cholesterol levels in the PLTP transgenic mice on the
high fat, high cholesterol diet were essentially the same as in
the control mice (Table I).
At the end of the 12-week diet period, PLTP activity, total
cholesterol, VLDL  LDL cholesterol, and HDL cholesterol
were measured (Table I). Total cholesterol does not increase
further between 4 and 12 weeks on the high fat, high choles-
terol diet. There is no difference between the various geno-
types. Also VLDL  LDL cholesterol is not significantly af-
fected in any group in comparison with control mice. In
contrast, HDL cholesterol is decreased in all human PLTP
expressing mice in comparison with control animals. In the
transgenic line with moderate expression of the PLTP trans-
gene, P1/LDLR/, a 60% reduction of HDL cholesterol was
FIG. 5. Atherosclerosis in transgenic PLTP, LDLR/ mice af-
ter 12 weeks of the atherogenic diet. a, representative cross-sec-
tions of the proximal aorta. The sections were stained with Oil Red O
and counterstained with hematoxilin. Scale bars, 200 m. b, lesion area
for individual animals and mean of the lesion area for each group
(horizontal line). p  0.001 versus LDLR/ mice for P4/LDLR/ mice,
A2/LDLR/ mice, and A3/LDLR/ mice.
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observed; in the other PLTP transgenic lines, this reduction
was more than 80%.
Fig. 5a shows representative photographs of the aortic root
sections with atherosclerotic lesions of the various groups after
12 weeks of the high fat, high cholesterol diet. Fig. 5b shows the
individual and mean atherosclerotic lesion areas. In the P1/
LDLR/ mice, there is a tendency toward more severe athero-
sclerosis than in controls, but the difference was not statistically
significant. However, in all other groups of PLTP transgenic
mice, the atherosclerotic lesion area is significantly increased.
The A2/LDLR/ mice, which have the highest level of plasma
PLTP activity, also have the highest atherosclerotic lesion area
(p  0.001; compared with all other transgenic lines).
DISCUSSION
In the present study, we found that elevation of plasma
PLTP activity has different effects on lipoproteins: secretion of
VLDL is increased, whereas plasma HDL-cholesterol levels are
decreased. In addition, we found a PLTP dose-dependent in-
crease of the development of atherosclerosis.
Lines A3 (hepatocyte-specific expression) and P4 (not liver-
specific) have comparable plasma PLTP activity levels and
show no statistically significant differences in any of the pa-
rameters studied here. Thus, the effects described in this report
are likely caused by plasma PLTP, regardless of the site of
synthesis.
Although there is a stimulatory effect of PLTP on VLDL
secretion by the liver, this effect seems to be saturated by
moderately increased PLTP expression. Therefore, the effect of
PLTP on VLDL secretion is an unlikely explanation for the
increase in the development of atherosclerosis that we found in
PLTP transgenic mice. On the other hand, plasma HDL levels
are clearly related to the activity levels of plasma PLTP. In the
highest expressing line of PLTP transgenic mice (A2), both
HDL cholesterol and HDL protein (apoAI) were virtually ab-
sent from plasma, a result also found in adenoviral transfected
mice that express very high levels of PLTP (17, 18). This is
explained by the surface activity of PLTP on phospholipids in
the outer shell of the HDL particles, causing instability and
increased HDL catabolism (18). In preliminary studies, we
found that plasma decay of labeled HDL cholesterylether is
accelerated in our PLTP transgenic mice.2 The decrease in
apoAI/HDL is probably not the result of decreased apoAI syn-
thesis, because hepatic apoAI mRNA levels are unchanged in
both of the PLTP transgenic lines (Fig. 1c). From the present
studies it is clear that PLTP lowers plasma HDL in mice fed a
high fat, high cholesterol diet, whereas VLDL/LDL levels re-
main unchanged by expression of human PLTP (Table I).
There is a large body of evidence showing an inverse rela-
tionship between circulating levels of HDL and the incidence of
atherosclerosic disease. Low levels of plasma HDL are gener-
ally associated with an increased risk for the development of
atherosclerosis. The initial finding that apoAI-deficient mice
did not show atherosclerosis (30) remained a single observa-
tion, which is probably due to the fact that the mice were not
backcrossed to an atherosclerosis-prone genetic background.
Later it was found that apoAI deficiency does result in en-
hanced atherosclerosis in atherosusceptible backgrounds (31,
32). The underlying molecular mechanism of the atheroprotec-
tive effect of HDL is complex because HDL has multiple func-
tions that contribute to this relationship. These include a key
role in reverse cholesterol transport, antioxidant effects via
proteins associated with HDL like paraoxonase, and anti-in-
flammatory properties of HDL (4, 33–36).
Previously, we and others suggested that overexpression of
PLTP resulted in an increase in the anti-atherogenic potential
of HDL, because of an increased formation of pre--HDL in
plasma (14, 16, 18). In addition, plasma from PLTP transgenic
animals was more efficient in preventing the accumulation of
cholesterol by cultured macrophages (14). Still, the present
study shows that atherosclerosis is increased in mice overex-
pressing PLTP. From these in vivo experiments we conclude
that the decrease in total HDL apparently is the deciding factor
and not a possible effect on pre--HDL. This conclusion is
corroborated by recent findings bringing the key role of pre--
HDL in cellular cholesterol efflux under discussion (37).
We conclude that high plasma activity levels of PLTP are
atherogenic via a lowering effect on HDL cholesterol. The ele-
vations in plasma PLTP activity in the transgenic mice we used
started at 2-fold. Until now, such differences have not been
found in humans. However, atherosclerosis is a long term proc-
ess, taking several decades in humans. This process has to be
accelerated to be able to do studies in genetically modified
animals. Therefore, models are used with substantial overex-
pression, which have proven to be very informative for proteins
involved in cholesterol metabolism, including ABCA1 (38),
apoA-IV (39), cholesteryl ester transfer protein (40), and leci-
thin:cholesterol acyltransferase (41). Actually, PLTP trans-
genic mice with an elevated activity of 30% have been gener-
ated and showed no effects on plasma lipids and lipoproteins
(16). Mice with only one functional PLTP allele (PLTP/) do
not have any abnormalities in lipoproteins when fed normal
chow or a high fat, high cholesterol diet (19). Therefore, phys-
iological PLTP levels might be considered “high.” It is conceiv-
able that moderate differences in PLTP levels found among
humans might affect the life-long process of the development of
atherosclerotic disease. Until now, mutations in the PLTP gene
resulting in differences in PLTP activity have not been found.
However, the available data show high PLTP activity levels in
conditions that have been associated with an increased risk of
coronary artery disease, i.e. diabetes type 1 and 2, and obesity
(12, 42, 43). Together with mouse data described here, this
implies that high PLTP activity is a potential risk factor for
coronary artery disease in humans.
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